Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2024-11-20 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
回购报告书
Transaction in Own Shares Classification · 100% confidence The document is titled as a "回购报告书" which translates to a "Share Repurchase Report" or "Buyback Report." It details the company's plan to repurchase its own shares, including the purpose, amount, price range, funding sources, implementation period, and risk factors. It also includes information about board approval, authorization, and disclosures related to the repurchase. The document is comprehensive and contains substantive details about the share buyback program, not just an announcement or a brief notice. This matches the definition of a "Transaction in Own Shares" filing, which reports on the company's buyback of its own shares. Therefore, the correct classification is POS (Transaction in Own Shares). The document length (8317 characters) and detailed content support this classification with high confidence.
2024-11-20 Chinese
第十一届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Changchun High-tech Industry (Group) Co., Ltd., detailing decisions made at the 11th Board of Directors 6th meeting held on November 14, 2024. It includes voting results on share repurchase and convertible bond listing proposals. The content focuses on board decisions and approvals rather than financial results or detailed reports. The document length is short (1973 characters) and it is a formal announcement of board resolutions, not a full management report or financial statement. Therefore, it fits best under Board/Management Information (MANG).
2024-11-15 Chinese
关于公司回购股份方案暨取得金融机构股票回购专项贷款的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding a company's plan to repurchase its own shares, including the purpose, conditions, funding sources, implementation period, risks, and board authorization. It discusses the use of repurchased shares for employee stock ownership plans and equity incentives. The document includes financial data related to the repurchase and compliance with regulatory requirements. This is a classic example of a share repurchase announcement, which fits the category of 'Transaction in Own Shares' (POS). It is not a full financial report, earnings release, or management report, but a specific capital action announcement. The document length and content confirm it is not a brief notice or a report publication announcement but a substantive announcement of a share buyback plan.
2024-11-15 Chinese
关于子公司聚乙二醇重组人生长激素注射液新适应症上市申请获得国家药监局批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High & New Technology Industries (Group) Co., Ltd. regarding the approval of a new indication for a subsidiary's pharmaceutical product by the National Medical Products Administration (NMPA) of China. It details the product, the approval, clinical trial results, and potential impact on the company. The document is short (1224 characters) and serves as an official announcement of regulatory approval rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management changes. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory approval announcement. The best fitting category is Regulatory Filings (RNS) as it is a general regulatory announcement about product approval and company impact without fitting other specific categories.
2024-11-05 Chinese
关于完成工商变更登记并换发营业执照的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (678 characters) regarding the completion of a business registration change and issuance of a new business license. It mentions board and shareholder meetings approving capital changes and stock repurchases, but does not contain detailed financial statements or comprehensive report content. It references other announcements for detailed resolutions. The document is an official notice about a corporate registration update and capital change, not a full financial report or detailed management discussion. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about corporate changes without substantive financial data or report content.
2024-10-28 Chinese
关于为子公司申请银行授信提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Changchun High-tech Industry Group Co., Ltd. regarding providing a guarantee for a bank credit application by its subsidiary. It details the guarantee terms, the involved companies, financial data, and board approval. The document is an announcement of a financing-related guarantee and does not contain a full financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive information about the guarantee. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees for loans.
2024-10-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.